Catherine Skari
-
Oct- 2020 -7 OctoberNews
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced…
Read More » -
6 OctoberTIF News
TIF Develops Mobile Application To Support Patients With Thalassaemia
As part of its enduring efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF will…
Read More » -
4 OctoberNews
Coming Up This Week: ”Iron Monitoring in Thalassaemia” Webinar for Patients
Although chronic blood transfusion regimens have added decades to the lives of patients with thalassaemia, clinicians are now faced with…
Read More » -
2 OctoberMember News
Pancyprian Thalassaemia Conference 2020
Τhe Pancyprian Thalassaemia Conference 2020 was successfully held on Saturday, 26 September, to discuss the modern scientific and other developments…
Read More » -
2 OctoberClinical News
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to…
Read More » -
Sep- 2020 -30 SeptemberWebinars
THAL e-COURSE: Liver Disease in Thalassaemia by Prof. John Koskinas
Meeting your continuing educational needs on thalassaemia has never been easier! The 1st Webinar to inaugurate the TIF Thal e-Course…
Read More » -
30 SeptemberNews
Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment…
Read More » -
29 SeptemberTIF News
TIF Takes Active Part At The IAPO 9th Global Patients Congress
The International Alliance of Patients’ Organizations (IAPO) conducted online the 9th Global Patients Congress #GPC2020 on 16-17 September 2020, under…
Read More » -
25 SeptemberNews
Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle…
Read More » -
24 SeptemberNews
Iranian Blood Transfusion Organization Newsletter – August 2020
The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Read More »